| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8afdfc8f7b80752223680a5da978c42b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26305701f496742ebac035bd10b7aab9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
| filingDate |
2007-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34e74522f4b77637d0c5f946aa4ebfdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3fb024a0f7fc8feea4b018e961834b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3041688698e0efc3cf1a0a0d2f00131f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e703d5c3c8909a25bbb852a348a4ca0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1b5e6b52de53cdafd366af1bd258b08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fdcd287647ae4f2185633f27c816452 |
| publicationDate |
2011-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-570152-A |
| titleOfInvention |
XAF-1, a diagnostic marker for interferon responsiveness in multiple sclerosis |
| abstract |
Provided is a method of determining interferon responsiveness in a patient suffering from quiescent secondary progressive multiple sclerosis and/or active secondary progressive multiple sclerosis, the method comprising: 5 (a) determining an amount of a XAF-I gene expression level in a blood sample obtained from the patient, the patient being treated with the interferon; and (b) correlating the amount of the XAF-1 gene expression level in the blood sample with the responsiveness of the patient to the interferon. |
| priorityDate |
2006-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |